P070006/S028: T-SPOT.TB Test
FDA’s recorded scope: a supplier increase in manufacturing scale
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 2 FDA records to the applicant name Oxford Immunotec, Ltd.. 1 entry is a PMA supplement. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Aug 4, 2025 to Aug 4, 2025. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code OJN appears in 2 of the 2 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P070006, with 2 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: 94c Innovation Dr., Milton Park, Abingdon Oxfordshire, OX14 4RZ. Recorded on P070006/S028, decision dated Aug 4, 2025.
Mycobacterium tuberculosis, Cell mediated immune response, enzyme-linked immunospot test.
FDA’s recorded scope: a supplier increase in manufacturing scale
FDA’s recorded scope: Approval for three changes to the T-Cell Select reagent kit: to change the concentration of one antibody reagent, to add an alternative supplier of both antibody reagents, and to extend the open container shelf life.
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.